Mdm2 and the p53 pathway in human pituitary adenomas

Clinical Endocrinology

Volumn 54, Issue 3, 2001, Pages 317-325

  Suliman, Mohamed ^a   Royds, Janice ^b   Cullen, Derek ^a   Timperley, Walter ^a   Powell, Tom ^a   Battersby, Robert ^a   Hugh Jones, T ^b,c  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KI 67; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ISOLATION; SIGNAL TRANSDUCTION; TRANSSPHENOIDAL SURGERY; TUMOR GROWTH;

ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NUCLEAR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PITUITARY GLAND; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035068301     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2001.01195.x     Document Type: Article

References (45)

1. Interleukin involvement in anterior pituitary cell growth regulation: Effects of IL-2 and IL-6
2. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker
3. p53 protein accumulation in Cushing's adenomas and invasive nonfunctional adenomas
4. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis
5. WAF-1, a potential mediator of p53 tumour suppression
6. Epidemiology and pathogenesis of pituitary adenomas
7. Tumour suppressor genes in pituitary tumour formation
8. Cytokine expression in human anterior pituitary adenomas
9. Apoptosis and p53 tumour suppressor gene protein expression in human anterior pituitary adenomas
10. p53 in tumour pathology: Can we trust immunocytochemistry?-revisited
11. p53 - Integrating the complexity
12. Transsphenoidal microsurgical treatment of pituitary tumours
13. The p21 Cdk-interacting Protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
14. Molecular screening of pituitary adenomas for gene mutations and rearrangements
15. Clonal origin of pituitary adenomas
16. Molecular analysis of p21 and p27 genes in human pituitary adenomas
17. A human pituitary adenoma cell line proliferates and maintains some differentiated functions following expression of SV40 large T-antigen
18. Production of bioactive and immunoreactive interleukin-6 and expression of IL-6 mRNA by human pituitary adenomas
19. Outcome of surgery for acromegaly
20. Proliferation activity in pituitary adenomas: Measurement by monoclonal antibody Ki-67
21. Growth rate of human pituitary adenomas
22. p53, guardian of the genome
23. Mdm2 - Arbiter of p53's destruction
24. p53 gene mutations in pituitary adenomas: Rare events
25. Induction of WAF1/CIP1 by a p53-independent pathway
26. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
27. Amplification of a gene encoding a p53-associated protein in human sarcomas
28. Isolation and characterization of a pituitary tumor-transforming gene (PTTG)
29. H-ras mutations in human pituitary carcinoma metastasis
30. The p53 pathway
31. Pituitary cytokine and growth factor expression and action
32. Why is p53 protein stabilised in neoplasia? Some answers but many more questions!
33. Pituitary tumour pathogenesis
34. Hypermethylation of the p16/CDKN2A/MTS/ gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas
35. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island
36. Chromosome 13q deletion mapping in pituitary tumours: Infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite loss of RB1 protein product in somatotrophinomas
37. Interleukin-8 mRNA expression by in-situ hybridisation in human pituitary adenomas
38. Immunocytochemical expression of p53, p21waf1 and mdm2 in human anterior pituitary adenomas
39. Immunohistochemical study of p53 protein in human and animal pituitary tumours
40. p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumour growth fractions
41. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: An analysis using the MIB-1 antibody
42. p21 (WAF1/CIP1) antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis
43. Are markers of proliferation valuable in the histological assessment of pituitary tumours?
44. Commentary: The influence of cell context on the selection pressure for p53 mutatin in human cancer
45. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas